{"id":"prevenar-13-and-synflorix","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site erythema"},{"rate":"5-20","effect":"Injection site swelling"},{"rate":"20-40","effect":"Injection site pain"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Irritability"},{"rate":"5-10","effect":"Drowsiness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These vaccines contain polysaccharide antigens from different serotypes of S. pneumoniae conjugated to protein carriers, which enhances immunogenicity and T-cell dependent responses. The vaccines prime the adaptive immune system to recognize and neutralize pneumococcal pathogens, providing protection against invasive pneumococcal disease and pneumonia. Prevenar 13 covers 13 serotypes while Synflorix covers 10 serotypes, with some overlap and differences in serotype coverage.","oneSentence":"Prevenar 13 and Synflorix are pneumococcal conjugate vaccines that stimulate the immune system to produce antibodies against Streptococcus pneumoniae serotypes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:13.121Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease caused by susceptible serotypes"},{"name":"Prevention of pneumococcal pneumonia"},{"name":"Prevention of pneumococcal otitis media"}]},"trialDetails":[{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT03489018","phase":"PHASE4","title":"The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-03-21","conditions":"Pneumococcal Infection, Streptococcus Pneumoniae Infection, Invasive Pneumococcal Disease, Protection Against","enrollment":2100},{"nctId":"NCT04275284","phase":"","title":"Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2020-02-14","conditions":"Pneumonia, Meningitis","enrollment":600},{"nctId":"NCT05721456","phase":"PHASE3","title":"Evaluation of the Non-Inferiority of a 12-Valent Pneumococcal Conjugate Vaccine in Healthy Children in Brazil.","status":"UNKNOWN","sponsor":"Maria de Lourdes de Sousa Maia, MD","startDate":"2023-08-28","conditions":"Pneumococcal Vaccines","enrollment":2400},{"nctId":"NCT01953510","phase":"PHASE2, PHASE3","title":"Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2013-09-30","conditions":"Pneumococcal Vaccines","enrollment":1400},{"nctId":"NCT03896477","phase":"PHASE3","title":"Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2019-07-18","conditions":"Pneumonia, Pneumococcal","enrollment":660},{"nctId":"NCT01641133","phase":"PHASE3","title":"Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09-04","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":457},{"nctId":"NCT04551248","phase":"","title":"Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2021-08-01","conditions":"Pneumococcal Vaccine Adverse Reaction","enrollment":1000000},{"nctId":"NCT01735084","phase":"PHASE4","title":"Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2013-03-12","conditions":"Otitis Media, Febrile Illness, Cough","enrollment":261},{"nctId":"NCT02943902","phase":"PHASE3","title":"Reduced PCV Dosing Schedules in South African Infants","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2017-01-09","conditions":"Pneumonia, Meningitis","enrollment":600},{"nctId":"NCT02918708","phase":"PHASE4","title":"Assessment of Novel Pneumococcal Conjugate Vaccination Scheduled in UK Infants","status":"WITHDRAWN","sponsor":"Public Health England","startDate":"","conditions":"Vaccination, Immunization","enrollment":""},{"nctId":"NCT01616459","phase":"PHASE2","title":"Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07-11","conditions":"Infections, Streptococcal","enrollment":953},{"nctId":"NCT01746108","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-06-18","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":52},{"nctId":"NCT00652951","phase":"PHASE3","title":"Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-01","conditions":"Infections, Streptococcal","enrollment":780},{"nctId":"NCT01262872","phase":"PHASE2","title":"Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-09","conditions":"Infections, Streptococcal","enrollment":1320},{"nctId":"NCT01204658","phase":"PHASE2","title":"Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-27","conditions":"Infections, Streptococcal","enrollment":576},{"nctId":"NCT01174849","phase":"PHASE4","title":"Pneumococcal Vaccines Early and in Combination","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2011-08","conditions":"Otitis Media","enrollment":425},{"nctId":"NCT01443416","phase":"PHASE3","title":"An Alternative Booster Vaccine Against Meningitis and Ear Infections","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-04","conditions":"Invasive Streptococcus Pneumoniae Disease","enrollment":178},{"nctId":"NCT01619462","phase":"PHASE3","title":"Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children","status":"UNKNOWN","sponsor":"Papua New Guinea Institute of Medical Research","startDate":"2011-11","conditions":"Pneumonia, Meningitis, Bacteraemia","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Synflorix(R), PCV10","Prevenar 13(R), PCV13"],"phase":"phase_3","status":"active","brandName":"Prevenar 13 and Synflorix","genericName":"Prevenar 13 and Synflorix","companyName":"Papua New Guinea Institute of Medical Research","companyId":"papua-new-guinea-institute-of-medical-research","modality":"Biologic","firstApprovalDate":"","aiSummary":"Prevenar 13 and Synflorix are pneumococcal conjugate vaccines that stimulate the immune system to produce antibodies against Streptococcus pneumoniae serotypes. Used for Prevention of invasive pneumococcal disease caused by susceptible serotypes, Prevention of pneumococcal pneumonia, Prevention of pneumococcal otitis media.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}